PMID- 31463257
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220410
IS  - 2249-4863 (Print)
IS  - 2278-7135 (Electronic)
IS  - 2249-4863 (Linking)
VI  - 8
IP  - 7
DP  - 2019 Jul
TI  - Investigating the effect of sildenafil on improving lung function and quality of 
      life in the patients with severe asthma.
PG  - 2361-2363
LID - 10.4103/jfmpc.jfmpc_334_19 [doi]
AB  - INTRODUCTION: Phosphodiesterase inhibitors (PDEs) increase intracellular cyclic 
      adenosine monophosphate, which results in a wide range of anti-inflammatory 
      effects and pathologically leads to improve asthma disease. Because no human 
      study has surveyed the effect of PDEs on pulmonary function, except some case 
      reports and animal researches, we decided to perform a pilot study for evaluating 
      the effect of sildenafil (PDE5) on pulmonary function in patients with severe 
      asthma. METHODS: This randomized controlled trials study was conducted on 20 
      patients with severe asthma in 2019 in Iran. For case group, was prescribed 
      sildenafil (50 mg) daily and the control group received the placebo. In the 
      beginning of the study and one month later, volume parameters, 6-minute walk 
      distance (6MWD), and the quality-of-life questionnaire were measured and compared 
      in the two groups. RESULTS: Twenty patients were entered into this study. 8 
      patients (40%) were male and 12 (60%) were female. The results showed that mean 
      forced vital capacity 1 in the sildenafil group turned from 1259 +/- 170 to 1603 +/- 
      527, while in the placebo group it changed from 1135 +/- 125 to 1365 +/- 251 (P-value 
      = 0.215). There is no statistically significant difference between two groups. In 
      addition, in comparison with placebo, sildenafil did not show any significant 
      improvement in the volume parameters, the quality-of-life questionnaire scale, 
      and 6MWD at the end of the study. CONCLUSION: According to present result can be 
      concluded that sildenafil does not improve the severity of asthma and the quality 
      of life in patients with severe asthma.
FAU - Borsi, Hamid
AU  - Borsi H
AD  - Department of Pulmonology, Air Pollution and Respiratory Diseases Research 
      Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
FAU - Raji, Hanieh
AU  - Raji H
AD  - Department of Pulmonology, Air Pollution and Respiratory Diseases Research 
      Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
FAU - Shoushtari, Maryam Haddadzadeh
AU  - Shoushtari MH
AD  - Department of Pulmonology, Air Pollution and Respiratory Diseases Research 
      Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
FAU - Tavakol, Heshmatollah
AU  - Tavakol H
AD  - Department of Pulmonology, Air Pollution and Respiratory Diseases Research 
      Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
FAU - Haghighizadeh, Mohammad Hossein
AU  - Haghighizadeh MH
AD  - Department of Statistics and Epidemiology, Faculty of Health, Ahvaz Jundishapur 
      University of Medical Sciences, Ahvaz, Iran.
FAU - Mal-Amir, Mehrdad Dargahi
AU  - Mal-Amir MD
AD  - Department of Pulmonology, Air Pollution and Respiratory Diseases Research 
      Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
LA  - eng
PT  - Journal Article
PL  - India
TA  - J Family Med Prim Care
JT  - Journal of family medicine and primary care
JID - 101610082
PMC - PMC6691445
OTO - NOTNLM
OT  - Lung volumes
OT  - quality of life
OT  - severe asthma
OT  - sildenafil
COIS- There are no conflicts of interest.
EDAT- 2019/08/30 06:00
MHDA- 2019/08/30 06:01
PMCR- 2019/07/01
CRDT- 2019/08/30 06:00
PHST- 2019/08/30 06:00 [entrez]
PHST- 2019/08/30 06:00 [pubmed]
PHST- 2019/08/30 06:01 [medline]
PHST- 2019/07/01 00:00 [pmc-release]
AID - JFMPC-8-2361 [pii]
AID - 10.4103/jfmpc.jfmpc_334_19 [doi]
PST - ppublish
SO  - J Family Med Prim Care. 2019 Jul;8(7):2361-2363. doi: 10.4103/jfmpc.jfmpc_334_19.